Search the Newsreel

ePlus Number of Employees 2026 | Employee Count & Headcount Data

ePlus, Inc. had approximately 2,155 employees worldwide as of March 2026, marking a 2.8% decline from 2023. The company is actively hiring, with 154 active job postings in 2026, a significant increase from the previous year. Most of its workforce is in the United …

Lazard Asset Management LLC Purchases Shares of 47,854 ePlus inc. $PLUS

Lazard Asset Management LLC recently acquired 47,854 shares of ePlus inc. (NASDAQ:PLUS) for approximately $3.6 million in the first quarter, bringing institutional ownership to 93.8%. Despite the company exceeding quarterly earnings and revenue estimates and increasing its dividend, analyst sentiment remains cautious with a …

Repligen Corp (RGEN) Institutional Confidence

Repligen Corp (RGEN) has an institutional confidence score of 10.00, placing it first in its industry. Institutional shareholding increased by 3.23% quarter-over-quarter, with Lee Ainslie being the largest shareholder. The article lists the top institutional shareholders and their recent activity.

Replimune Group, Inc. Actuals & Estimates (NASDAQ:REPL)

This article provides an overview of Replimune Group, Inc. (NASDAQ:REPL) financial actuals, estimates, and stock performance. It covers current stock price, historical highs and lows, market capitalization, earnings reports, and analyst forecasts. The article also addresses frequently asked questions about investing in REPL stock …

This Biotech Stock Soars 107% After Key FDA Panel Vote on Skin Cancer Treatment

Replimune Group's stock surged by 107% after an FDA panel voted 10-3 in favor of its experimental skin cancer treatment. This positive vote indicates a significant step forward for the biotechnology company's new therapy.

ePlus (NASDAQ:PLUS) CFO Elaine Marion Sells 2,818 Shares of Stock

ePlus CFO Elaine Marion sold 2,818 shares of the company's stock on July 29th for a total value of approximately $268,330. The company's stock is trading near its 52-week high, and its latest quarterly results exceeded expectations, with EPS of $1.00 and revenue of …

EPLUS Inc (PLUS) CFO sells 2,818 shares under Rule 10b5-1 trading plan

EPLUS Inc. CFO Elaine D. Marion reported selling a total of 2,818 shares of common stock on July 29, 2026, through open-market transactions under a Rule 10b5-1 trading plan. A revocable trust associated with her sold 2,394 shares at a weighted average price of …

Top Midday Gainers

Replimune (REPL) stock soared 94% after the company late Thursday reported a favorable outcome of the US Food and Drug Administration's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in advanced melanoma.The committee voted 10 to 3 that the efficacy Silver Upgrade …

Replimune rebounds as positive AdCom vote prompts Cantor upgrade

[Wall Street New York stock exchange stock market] alexsl Despite a multi-day decline earlier this week, Replimune (REPL [https://seekingalpha.com/symbol/REPL]) shares bounced back on Friday as Cantor Fitzgerald upgraded the biotech after an FDA advisory committee voted in favor of the company’s lead, RP1, targeted …

Vanguard Capital Management reports 5% Repligen (RGEN) stake in Schedule 13G

Vanguard Capital Management has disclosed a 5% beneficial ownership stake in Repligen Corp (RGEN) through a Schedule 13G filing. This represents 2,825,579 shares of common stock, with Vanguard holding sole voting power over 414,408 shares and sole dispositive power over all 2,825,579 shares. The …

Replimune Skin Cancer Therapy Hopes Revive After Positive FDA Panel Vote

Replimune Group's shares more than doubled after a positive FDA advisory committee vote on its IGNYTE study data for RP1 in combination with nivolumab for advanced melanoma. The committee voted 10 to 3 that the study results are clinically meaningful and evaluable, despite previous …

FDA advisory panel backed Replimune's twice-rejected melanoma treatment in 10-3 vote

An FDA advisory panel voted 10-3 in favor of Replimune's experimental melanoma treatment, RP1, increasing its chances of approval despite two prior rejections and concerns from FDA scientists about the trial data. The decision comes ahead of an August 2 deadline for the FDA …

Stocks making the biggest moves premarket: Replimune, Chevron, Apple, Amazon, Moderna & more

Check out the companies making the biggest moves premarket: Replimune Group — Shares were up over 130% for the clinical-stage biotechnology company after a Food and Drug Administration advisory panel voted in favor of the company's RP1 drug trial results for a type of …

Replimune stock upgraded at Cantor on FDA vote (REPL:NASDAQ)

Replimune (REPL) shares rebounded following an upgrade by Cantor Fitzgerald. The upgrade came after an FDA advisory committee voted favorably for the company's lead drug, RP1, which targets melanoma. This positive development occurred despite a prior multi-day decline in the stock earlier in the …

REPL Stock Jumps As FDA Panel Backs Melanoma Drug

Replimune Group Inc. (REPL) stock jumped significantly after an FDA advisory panel voted 10-3 in favor of the efficacy data for its melanoma therapy, RP1 plus nivolumab, from the IGNYTE trial. This positive recommendation de-risks the company's ongoing Biologics License Application (BLA) resubmission ahead …

Replimune stock surges on positive AdCom vote (REPL:NASDAQ)

Replimune's stock more than doubled in post-market trading after the FDA's Cellular, Tissue, and Gene Therapies Advisory Committee voted favorably on the company's lead asset, RP1. This positive AdCom vote precedes a key target date of August 2. The significant surge indicates strong investor …

FDA Panel Votes In Favor of Replimune’s Melanoma Treatment

An FDA advisory panel voted 10-3 in favor of Replimune Group's experimental melanoma therapy, despite regulators' earlier concerns about the trial design and data. This recommendation follows a contentious meeting and a significant drop in Replimune's stock price after a critical FDA analysis. The …

Replimune Announces Favorable Outcome of FDA's Cellular, Tissue, and Gene Therapies Advisory Committee Meeting for RP1 in Advanced Melanoma

WOBURN, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced the outcome of today's meeting of the U.S. Food and Drug Administration's (FDA) Cellular, Tissue, and Gene Therapies …

Insider Selling: ePlus (NASDAQ:PLUS) COO Sells $182,006.10 in Stock

ePlus COO Darren Raiguel recently sold 1,935 shares of ePlus stock for a total of $182,006.10, reducing his ownership by 2.72% but still retaining a significant stake. The sale occurred despite ePlus exceeding quarterly earnings expectations and increasing its dividend. Analysts, however, currently hold …

Bragar Eagel & Squire, P.C. is Investigating Replimune

Bragar Eagel & Squire, P.C., a stockholder rights law firm, is investigating potential claims against Replimune Group Inc. following a significant stock drop. The investigation comes after the FDA deemed Replimune's single-arm mid-stage study for its drug RP1 for skin cancer as "not interpretable," …

ePlus Inc (PLUS) COO’s trust sells 2,000 shares via 10b5-1 plan

Darren S. Raiguel, COO of ePlus Inc (PLUS), reported that a revocable trust for which he and his spouse are trustees sold 2,000 shares of common stock on July 28–29, 2026. The sales were executed under a Rule 10b5-1 trading plan adopted on November …

Repligen (RGEN) Stock Faces A Margin Puzzle After Revenue Growth

Repligen (RGEN) recently reported Q2 2026 earnings with revenue growth and expanded adjusted gross and operating margins, despite a slip in net income. The article discusses the bull and bear cases for the stock, focusing on the company's shift towards recurring revenue and its …

Replimune’s RP-1 for melanoma wins over FDA adcom

Replimune Group Inc.'s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma, refractory to PD-1 therapy, received a positive vote from the U.S. FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee. The committee voted 10-3 that the efficacy results from the Ignyte phase II study …

Replimune: 'Sell' Continued Doubt On Single-Arm IGNYTE Trial For RP1 FDA Review (REPL)

Replimune Group, Inc. has been downgraded to 'Sell' due to ongoing FDA concerns regarding its RP1 + OPDIVO combination for advanced melanoma. The FDA's briefing documents highlight issues with the reliance on the single-arm IGNYTE trial, lack of a control arm, and a questionable …

Wall Street Analysts Believe Repligen (RGEN) Could Rally 25.72%: Here's is How to Trade

Repligen (RGEN) closed the last trading session at $141.23, gaining 1.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of …

Replimune Faces FDA Panel on RP1 Melanoma Therapy

Replimune will present data for its RP1 plus nivolumab therapy for advanced melanoma to an FDA advisory panel. The company is seeking accelerated approval for RP1, citing positive outcomes from the IGNYTE trial and previous FDA feedback, arguing its efficacy and safety profile justify …

Replimune Seeks FDA Advisory Committee Backing for RP1 + nivolumab; IGNYTE ORR 33.6% & DOR 24.8 mos

Replimune

Repligen (NASDAQ:RGEN) Combines Strong Growth with a Promising Technical Breakout Setup

Repligen (NASDAQ:RGEN) is highlighted as a compelling stock due to its strong fundamental growth, including significant revenue and EPS increases, combined with a promising technical breakout setup. The company shows an impressive growth rating with accelerating EPS expectations, despite an elevated valuation. Technically, RGEN …

ePlus (PLUS) to Release Earnings on Tuesday

ePlus (NASDAQ: PLUS) is scheduled to release its Q1 fiscal 2027 earnings after market close on Tuesday, August 4th. Analysts project earnings of $1.19 per share and revenue of $639.95 million. The company recently increased its quarterly dividend to $0.27 per share, while MarketBeat.com …

Dimensional Fund Advisors LP Acquires 48,158 Shares of ePlus inc. $PLUS

Dimensional Fund Advisors LP significantly increased its stake in ePlus inc. (

Replimune Group (REPL) Projected to Announce Quarterly Earnings on Thursday

ePlus inc (PLUS) Valuation: PE, PB & Fair Value Analysis

ePlus inc (PLUS) currently has a valuation score of 8.58, placing it 200th out of 485 companies in the Software & IT Services industry. Its P/E ratio is 18.42, which is significantly below its recent high and above its recent low. Other key valuation …

Replimune Group Number of Employees 2026 | Employee Count & Headcount Data

Replimune Group, a Pharmaceuticals company founded in 2015 and headquartered in Woburn, Massachusetts, had approximately 469 employees worldwide as of March 2026, representing a 35.9% growth from 2023 but a 1.2% decline year-over-year. The company's workforce is concentrated in the United States, followed by …

Repligen Corp Q2 2026: Revenue $204.1M, EPS $0.09— 10-Q Summary

Repligen Corp (RGEN) reported its second-quarter 2026 results, with revenue increasing by 11.9% year-over-year to $204.1 million. Despite the revenue growth, net income declined to $5 million, and diluted earnings per share fell to $0.09 from $0.26 in the prior-year quarter. The company also …

REPL: Replimune Group Inc Latest Stock Price, Analysis, News and Trading Ideas

This article provides a current overview of Replimune Group Inc. (REPL) stock, including its latest price, market performance, and financial fundamentals. It highlights recent news regarding a significant stock drop due to FDA documents and ongoing securities fraud investigations, alongside details on upcoming earnings …

REPL INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Replimune Group Inc. (“Replimune” or the “Company”) (NASDAQ: REPL). The investigation concerns whether the Company and/or members of its senior management may have violated …